TianTi Biotherapeutics is a biotechnology company that provides research and development of antibody drugs.
TianTi Biotherapeutics has raised $15.6M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
TianTi Biotherapeutics's investors include Cathay Capital, Oriza Holdings, Guangzhou Yuexiu Industrial Investment Fund, Shanghai Biomedical Industrial Equity Investment Fund, Kaitai Capital.
TianTi Biotherapeutics is headquartered in Woburn, United States.
TianTi Biotherapeutics is a biotechnology company that provides research and development of antibody drugs.
TianTi Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TianTi Biotherapeutics — Funding & Investors." VCBacked, December 20, 2021, https://www.vcbacked.co/company/tianti-biotherapeutics. Accessed August 14, 2026.
VCBacked. (2021). TianTi Biotherapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tianti-biotherapeutics
{{cite web |title=TianTi Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tianti-biotherapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated